The city has invested more than $1 billion in life science and biotech infrastructure in recent years to help New York entrants keep pace with companies hatched in the heavyweight clusters of Boston and San Francisco.
Those investments have paid off, with at least 10 thriving incubator programs—including [email protected] in Hudson Square, Johnson & Johnson’s JLabs in SoHo and the Alexandria Center for Life Science in Kips Bay—along with a small army of companies pursuing promising breakthroughs.
But a brewing storm of tax laws, market softness and supply chain problems could threaten the city’s meteoric rise as a life science player, reporter Shuan Sim wrote in his March
→ Continue reading at Crain's New York Business
